What should you expect after an Arthrosamid injection?

In the first few days after an Arthrosamid injection, the pattern most often described is mild local irritation in the treated knee rather than a serious reaction. Patient-facing aftercare and recovery guidance consistently mention pain or discomfort, swelling, stiffness, soreness, and sometimes some redness around the joint, particularly in the first 2–3 days. These early effects are usually presented as expected post-injection symptoms, not automatic signs that something has gone wrong, and simple measures such as rest, ice, elevation, gentle movement, and standard pain relief may be used where appropriate.

Beyond that early window, the bigger-picture safety data are broadly reassuring. In published follow-up at 52 weeks, 3 years, and 5 years, adverse events were reported over time, but the retrieved study abstracts did not attribute later or serious events to the device or to iPAAG. A 2022 systematic review covering 463 patients also described PAAG as safe in the available literature, with no long-lasting adverse events reported. That is reassuring, but it is not the same as saying side effects are impossible: worsening pain, or marked swelling, redness, or warmth, sits in a different category from the mild soreness and stiffness commonly described just after injection.

Which side effects seem most common?

Most of the side effects commonly described after Arthrosamid are local changes in the treated knee rather than a body-wide reaction. Patient information usually lists the same small group of symptoms together: pain or discomfort, swelling, stiffness, soreness or tenderness, and sometimes mild redness around the joint.

• 'Pain or discomfort': an achy or irritated feeling in the knee after the injection.
• 'Swelling': mild puffiness or a sense that the joint feels fuller than usual.
• 'Stiffness': the knee may feel tight or less easy to bend at first.
• 'Soreness' or tenderness: the area can feel bruised or sensitive for a short period.
• 'Redness': mentioned in some patient information, but usually as a mild local change rather than a major feature.

A December 2024 patient FAQ described 'mild swelling, redness, or discomfort', while aftercare guidance uses the phrase 'expected and normal' for pain, soreness, swelling, and stiffness. The practical point is that public materials do not clearly single out one symptom as the commonest; instead, they present a recognisable cluster of short-term post-injection knee irritation.

What can help with mild early reactions?

For the first 2–3 days, the aim of home care is usually to settle ordinary post-injection irritation rather than to treat a complication. Aftercare guidance describes rest, ice, elevation if helpful, and gentle movement as sensible ways to manage mild soreness, swelling, or stiffness during that early period. These measures sit firmly in the realm of symptom relief for the short-term reactions that are often described as part of recovery.

Pain relief is usually kept simple as well. Internal aftercare advice uses the phrase 'expected and normal' for early joint pain, soreness, swelling, and stiffness, and notes that paracetamol or ibuprofen may be used if appropriate for the individual, including over the first 2–3 days when discomfort may be more noticeable. That remains supportive care, not a substitute for review: if pain worsens rather than settles, or swelling becomes more significant, the treating clinician's advice should take priority, especially where there are other reasons to avoid NSAIDs or certain pain medicines.

When should you seek review?

The key dividing line is the pattern over the first few days, not the mere presence of symptoms. Mild soreness, stiffness or a little swelling can occur early on, but guidance becomes firmer when pain is "worsening rather than settles" instead of gradually easing.

Review is generally warranted if any of the following develop:

• Severe pain rather than ordinary post-injection soreness.
• Marked swelling or swelling that is becoming more obvious.
• Increasing redness or a knee that feels noticeably warm.
• Fever or a more general sense of feeling unwell.

Those features matter because they suggest a different picture from the short-term irritation described in routine aftercare. One patient-facing source specifically lists "severe pain, redness, swelling, or fever" as signs of possible complications, and recovery guidance also flags significant swelling, redness or warmth for review. When that pattern appears, prompt contact with the treating team is appropriate; if that is not possible and symptoms are severe, an appropriate urgent service is the safer route. A mild ache on its own is not the same pattern.

How reassuring is the longer-term safety data?

Beyond the first few days after injection, the accessible follow-up evidence is broadly reassuring rather than alarming. In a 52-week open-label study of 49 participants, investigators reported 8 adverse events between weeks 26 and 52, including 1 serious cerebrovascular accident, but none of those new events was thought to be device-related. A separate 3-year extension reported 50 adverse events in 36 of 119 Arthrosamid-treated participants between years 1 and 3, with none assessed as related to 2.5% iPAAG.

That same pattern continues in the longer reports. One 5-year open-label extension recorded 47 adverse events during follow-up, with no serious events attributed to the investigational device and no new adverse device effects reported. In another 5-year follow-up from the randomised trial programme, 79 adverse events were reported in 47 participants between years 1 and 5, and none was considered related to iPAAG.

A 2022 systematic review covering 463 patients reached a similar overall view, describing intra-articular PAAG as safe in the available literature and noting that no long-lasting adverse events had been reported. That is reassuring, but not the same as saying any treatment is risk-free. The main signal in the accessible evidence still centres on early local reactions, not a clear pattern of device-attributed serious long-term harm.

1. [1] A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. (2022). https://doi.org/10.18103/mra.v10i8.2950 https://doi.org/10.18103/mra.v10i8.2950